EMA grants OD for selumetinib in NF1
03 August 2018 07:00BST Selumetinib granted orphan designation in Europe for neurofibromatosis type 1 AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). NF1 is an incurable genetic condition that affects one in 3,000 newborns worldwide.1,2 The severity of signs and symptoms associated with NF1 can be highly variable, are often mild-to-moderate and may include